ELAN Q2 2020 Earnings — Elanco Animal Health Incorporated Revenue & Financial Results | Market Cap Arena

ELANElanco Animal Health Incorporated

$12B

Q2 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$586M-25.0% YoY

Gross Profit

$241M41.2% margin

Operating Income

$19M3.3% margin

Net Income

-$53M-9.1% margin

EPS (Diluted)

$-0.13

QoQ Revenue Growth

-10.9%

Cash Flow

Operating Cash Flow

$159M

Free Cash Flow

$144M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$9.9B

Total Liabilities

$3.2B

Stockholders' Equity

$6.7B

Cash & Equivalents

$1.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$586M	$782M	-25.0%
Gross Profit	$241M	$376M	-35.8%
Operating Income	$19M	$107M	-82.0%
Net Income	-$53M	$36M	-248.2%

Revenue Segments

Companion Animal Disease Prevention

$176M30%

Food Animal Ruminants And Swine

$158M27%

Food Animal Future Protein And Health

$158M27%

Companion Animal Therapeutics

$78M13%

Strategic Exits

$16M3%

Geographic Segments

Non-US

$338M58%

UNITED STATES

$248M42%